Mabwell(SH:688062)2026-01-23 08:05Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -900 million and -994.5 million yuan, indicating continued losses compared to the previous year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -905 million and -999.5 million yuan [2]. - The total profit for the previous year was -1,047.47 million yuan, with a net profit attributable to shareholders of -1,043.92 million yuan [3]. - The company will continue to report negative net profit attributable to shareholders for the 2025 fiscal year [6]. Revenue and Costs - The company reported a significant increase in operating income due to large revenue recognition from licensing agreements and increased drug sales compared to the previous year [4]. - Operating costs and sales expenses have increased in line with the expansion of commercialization efforts [4]. Research and Development - The company maintains a high level of R&D investment as multiple innovative drugs are in critical trial stages [4]. Forecast and Uncertainties - There are no significant uncertainties affecting the accuracy of this earnings forecast [7]. - The forecast data is preliminary and subject to change pending the audited financial report for 2025 [8].